Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 31;10(1):79.
doi: 10.1186/s40478-022-01383-y.

The polyG diseases: a new disease entity

Affiliations
Review

The polyG diseases: a new disease entity

Tongling Liufu et al. Acta Neuropathol Commun. .

Abstract

Recently, inspired by the similar clinical and pathological features shared with fragile X-associated tremor/ataxia syndrome (FXTAS), abnormal expansion of CGG repeats in the 5' untranslated region has been found in neuronal intranuclear inclusion disease (NIID), oculopharyngeal myopathy with leukoencephalopathy (OPML), and oculopharyngodistal myopathy (OPDMs). Although the upstream open reading frame has not been elucidated in OPML and OPDMs, polyglycine (polyG) translated by expanded CGG repeats is reported to be as a primary pathogenesis in FXTAS and NIID. Collectively, these findings indicate a new disease entity, the polyG diseases. In this review, we state the common clinical manifestations, pathological features, mechanisms, and potential therapies in these diseases, and provide preliminary opinions about future research in polyG diseases.

Keywords: Fragile X-associated tremor/ataxia syndrome; Neuronal intranuclear inclusion disease; Oculopharyngeal myopathy with leukoencephalopathy; Oculopharyngodistal myopathy; PolyG diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Typical brain radiological and pathological features in patient with NOTCH2NLC-CGG expansion. A and B Representative brain DWI image and T2-weighted image of patients with NOTCH2NLC-related polyG disease. C Representative H&E staining image show eosinophilic NIIs (black arrow) in sweat gland cells of skin D Representative immunostaining image show p62-positive NIIs (black arrow) in skin. E Representative electron microscopy image revealed Intranuclear tubulofilamentous inclusions in the skin of NIID patient. F Immunofluorescence against uN2CpolyG using 4D12 antibody (red, generously providing by Dr. Nicolas Charlet-Berguerand) and p62 antibody (green) on brain section from patient with NOTCH2NLC-CGG repeat expansion. Nuclei were counterstained with DAPI
Fig. 2
Fig. 2
Main mechanisms associated with polyG diseases. A CGG repeats are triplet nucleotides located in non-coding regions. There are two main pathogenesis mechanisms of non-coding CGG expansion related diseases. Mild and moderate CGG repeats can translate into polyglycine, and the protein toxicity causes neurodegeneration disorders, including FXTAS and NIID. In contrast, a high degree of repeated CGG sequences will lead to CpG island hypermethylation. Hypermethylation of CpG can lead to transcriptional gene silencing, resulting in partial or complete loss of the native protein encoded by the gene, resulting in abnormal FXS or asymptomatic NIID. B Hypotheses for the mechanism of nuclear inclusion body formation. CGG repeat RNAs can fold into complex structures, including hairpins, which aberrantly interact with and sequester RBPs into RNA foci. Non-coding RNA repeats could undergo canonical ribosome-dependent translation mechanism, thereby producing toxic polyG peptides. C Possible therapeutic approaches for polyG diseases. ASOs can bind to mRNA that contains pathological repeat expansions, inducing degradation of the target RNA. Small molecules can interact with mutant mRNA and break the hairpin structure. CRISPR/Cas9 technology can be used to excise portions of CGG repeats to inhibit methylation or translation of toxic proteins

Similar articles

Cited by

References

    1. Abati E, Bresolin N, Comi G, Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS) Expert Opin Ther Targets. 2020;24:295–310. doi: 10.1080/14728222.2020.1738390. - DOI - PubMed
    1. Abu Diab M, Mor-Shaked H, Cohen E, Cohen-Hadad Y, Ram O, Epsztejn-Litman S, Eiges R. The G-rich repeats in and loci are hotspots for local unpairing of DNA. Genetics. 2018;210:1239–1252. doi: 10.1534/genetics.118.301672. - DOI - PMC - PubMed
    1. Agtmaal EV, André L, Willemse M, Cumming SA, Kessel IV, van den Broek WJAA, Gourdon G, Furling D, Mouly V, Monckton DG. CRISPR/Cas9-Induced (CTGCAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther. 2017;25:24–43. doi: 10.1016/j.ymthe.2016.10.014. - DOI - PMC - PubMed
    1. Araki K, Sone J, Fujioka Y, Masuda M, Ohdake R, Tanaka Y, Nakamura T, Watanabe H, Sobue G. Memory loss and frontal cognitive dysfunction in a patient with adult-onset neuronal intranuclear inclusion disease. Intern Med. 2016;55:2281–2284. doi: 10.2169/internalmedicine.55.5544. - DOI - PubMed
    1. Bartlett E, Archibald AD, Francis D, Ling L, Thomas R, Chandler G, Ward L, O'Farrell G, Pandelache A, Delatycki MB, et al. Paternal retraction of a fragile X allele to normal size, showing normal function over two generations. Am J Med Genet A. 2021 doi: 10.1002/ajmg.a.62500. - DOI - PubMed

Publication types

Supplementary concepts